Romans 12:19
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
US Coronavirus: More than 20 states report an uptick in new Covid-19 cases after US tops 200,000 deaths http://a.msn.com/01/en-us/BB19kvQv?ocid=st
$RLFTF Besides COVID-19 What other Lung issues are they looking to treat using RLF-100 in the future? Thanks
Relief and Revive are brothers !!!!!
Looking good.. get those Bloomberg Bunnies into the fold...
$RLFTF WOW!! 2. For inhaled trial....some early info. 6 pts that could have proceeded to ICU were given inhaled version and all 6 home breathing their own air.
It's just a bookmark post..
RLFTF 0.607 0.036 (6.30%) Volume 17,063,575
NWBO Volume: 5,376,501
Thanks John
Wonder what Javitt will say today?
$RLFTF NEWS - GENEVA, Switzerland and RADNOR, Pa. , Sept. 21, 2020 /PRNewswire/ -- RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF) ("Relief" or the "Company") and NeuroRx, Inc.
- today announced the completion of their partnership agreement for the commercialization of RLF-100™(Aviptadil) worldwide.
The two organizations have agreed to share all profits from sales of RLF-100 for all indications related to COVID-19 and potentially other respiratory indications on a global basis.
They have agreed that NeuroRx will lead commercialization in the United States , Canada , and Israel , while Relief will lead commercialization in Europe and the rest of the world.
Profits from sales will be allocated to Relief and NeuroRx on a 50/50 basis in the U.S. , Canada and Israel , 85/15 (in favor of Relief) in Europe , and 80/20 (in favor of Relief) in all other territories.
The two companies have now taken steps to increase manufacturing of the aviptadil drug substance and are in the final stages of contracting with a fill/finish manufacturer, along with a national distribution partner. By January 2021 , Relief and NeuroRx expect to have manufacturing, distribution and logistics capacity in place to deliver sufficient drug quantities to treat 150,000 patients per month with RLF-100.
The companies continue to anticipate reporting top-line data from the ongoing randomized, double-blinded, placebo-controlled trial of intravenously-administered RLF-100 before the end of 2020.
The trial of inhalation-administered RLF-100 is slated to begin enrollment within the coming weeks.
As part of their agreement, Relief and NeuroRx intend to pursue the issuance of trademarks on RLF-100. NeuroRx shall prosecute such trademarks in the U.S. , Canada and Israel , while Relief shall prosecute trademarks in all other territories.
Raghuram (Ram) Selvaraju , Chairman of the Board of Relief , said: "We are pleased to reach this agreement with NeuroRx , a partner we believe is best suited to ensure rapid clinical development as well as timely and expedient interaction with regulatory authorities in what is likely to be the most important market for the drug, the United States .
We are looking forward to collaboratively and productively working together in order to maximize the value of the overall franchise for our shareholders and get this potentially life-saving drug to patients as swiftly as possible."
Jonathan C. Javitt , Chief Executive Officer of NeuroRx , added: "As the global pandemic continues to devastate families and communities, our small team is encouraged by the early promise we have seen in Sami Said's scientific legacy and we are working around the clock to bring this drug to patients."
$RLFTF NEWS - GENEVA, Switzerland and RADNOR, Pa. , Sept. 21, 2020 /PRNewswire/ -- RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF) ("Relief" or the "Company") and NeuroRx, Inc.
- today announced the completion of their partnership agreement for the commercialization of RLF-100™(Aviptadil) worldwide.
The two organizations have agreed to share all profits from sales of RLF-100 for all indications related to COVID-19 and potentially other respiratory indications on a global basis.
They have agreed that NeuroRx will lead commercialization in the United States , Canada , and Israel , while Relief will lead commercialization in Europe and the rest of the world.
Profits from sales will be allocated to Relief and NeuroRx on a 50/50 basis in the U.S. , Canada and Israel , 85/15 (in favor of Relief) in Europe , and 80/20 (in favor of Relief) in all other territories.
The two companies have now taken steps to increase manufacturing of the aviptadil drug substance and are in the final stages of contracting with a fill/finish manufacturer, along with a national distribution partner. By January 2021 , Relief and NeuroRx expect to have manufacturing, distribution and logistics capacity in place to deliver sufficient drug quantities to treat 150,000 patients per month with RLF-100.
The companies continue to anticipate reporting top-line data from the ongoing randomized, double-blinded, placebo-controlled trial of intravenously-administered RLF-100 before the end of 2020.
The trial of inhalation-administered RLF-100 is slated to begin enrollment within the coming weeks.
As part of their agreement, Relief and NeuroRx intend to pursue the issuance of trademarks on RLF-100. NeuroRx shall prosecute such trademarks in the U.S. , Canada and Israel , while Relief shall prosecute trademarks in all other territories.
Raghuram (Ram) Selvaraju , Chairman of the Board of Relief , said: "We are pleased to reach this agreement with NeuroRx , a partner we believe is best suited to ensure rapid clinical development as well as timely and expedient interaction with regulatory authorities in what is likely to be the most important market for the drug, the United States .
We are looking forward to collaboratively and productively working together in order to maximize the value of the overall franchise for our shareholders and get this potentially life-saving drug to patients as swiftly as possible."
Jonathan C. Javitt , Chief Executive Officer of NeuroRx , added: "As the global pandemic continues to devastate families and communities, our small team is encouraged by the early promise we have seen in Sami Said's scientific legacy and we are working around the clock to bring this drug to patients."
I don't care who takes the credit long as people are helped and I get paid!!!
Wildfire smoke leaves lung damage long after air clears https://www.sfgate.com/news/article/Wildfire-smoke-leaves-lung-damage-long-after-air-15578460.php?utm_campaign=CMS%20Sharing%20Tools%20(Desktop)&utm_source=t.co&utm_medium=referral via @SFGate
Wildfire smoke leaves lung damage long after air clears https://www.sfgate.com/news/article/Wildfire-smoke-leaves-lung-damage-long-after-air-15578460.php?utm_campaign=CMS%20Sharing%20Tools%20(Desktop)&utm_source=t.co&utm_medium=referral via @SFGate
We Wait.. House vote on marijuana legalization bill postponed after backlash from moderate lawmakers https://www.usatoday.com/story/news/politics/2020/09/17/marijuana-legalization-vote-postponed-after-backlash-moderates/3484129001/ via @usatoday
---
Hemp associations from all over the world join forces and speak out: industrial hemp is an agricultural product, not a drug https://finance.yahoo.com/news/hemp-associations-over-world-join-171300121.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr via @Yahoo
..Leaf,, IMO they're not walking away from their investments.. we've been in a pandemic.. people have not only trimmed back but lost business that they've built all their lives.. and it will probably pick back up with people returning to school and work.
..beside many, many pinks OTC run bare bones (save $$ on filing/PR's) and don't let shareholders in on the company.. OTC = Wild Wild West and most don't give a $%^^ and won't say I'm sorry.
.. the law has not really been in our favor and the mj.hemp trend is not hot at the moment but when it turns so will the share price.. IMO
..maybe you should look at the most active boards and flip a few others to get your mind off of this..
I remember him lying on a stock 7 years ago he should be in a cell with the pharma bro. .. they'd make a nice couple
Infection rates soar in college towns as students return https://www.sfgate.com/news/article/Infection-rates-soar-in-college-towns-as-students-15574721.php?utm_campaign=CMS%20Sharing%20Tools%20(Desktop)&utm_source=t.co&utm_medium=referral via @SFGate
Infection rates soar in college towns as students return https://www.sfgate.com/news/article/Infection-rates-soar-in-college-towns-as-students-15574721.php?utm_campaign=CMS%20Sharing%20Tools%20(Desktop)&utm_source=t.co&utm_medium=referral via @SFGate
Results and Saving Lives will overtake all the pettiness...
Fore!!!
The OTC is BRUTAL but Bad Chad will build you a nice car..
..you need to get his drill sergeant from boot-camp...
..golf course.. North .. North of what.. you use words like spot on and cheers.. and listen to punk rock.. I bet you have a real potty-mouth!! ;) a Scot maybe ?
... didn't deflect.. actually answered with the truth IMO and if people want answers here's the place to go.. https://www.meridacap.com/
Quote from original post: "still have other (well aware) investors on the board.. so I'm guessing everything that's been going on and not going on has been by design"
..whatever.. it's just entertainment now.. not selling at .79 in Oct 19 was the day I f'd myself on this deal.. what are you drunk posting ? maybe a bunch of you should head down to Texas and talk to the guy in person.. make sure you get a bunch wheel barrows to carry your internet balls with ya..
Nice try MC, I do like the points but to be fair to the posts and narrative you are replying to - you need to address the points raised. Not re-direct. I particularly like the whole honesty angle. I also like the hitting just below the belt "are you a man or a mouse" thing - only in the sense that it plays into the sterotype machismo latino.. sleep with many women.. fuck with many shareholder kind of thing. I like it but I don't agree with it. Anyhow, if it gets a straight answer or a gay one that would be something new ;).
Let's go!.. GRLB$
..some heavy hitters involved.. but how can they avoid Javitt.. he's been around the block and mixed w/these people wearing many of the coats on all sides of this.. only thing that makes sense would be the excitement of how well it works and they all want to be apart of it..
----------
In some cases, the data monitoring board for a trial would be faced with deciding whether to stop that study. “You don’t want three well-intentioned friends being spoon-fed information from the trial and who can’t look at it critically,” Turner added.
https://www.politico.com/news/2020/09/17/andy-harris-coronavirus-neurorx-board-417329?fbclid=IwAR1NPy1TMvO7_kMkDr89t-5TbtPSAVPNffVHqYpWJVgjOw0MD-f0H79Oh0Q
..could it be that during the pandemic they just trimmed expenses to the bare bone? ..still have other (well aware) investors on the board.. so I'm guessing everything that's been going on and not going on has been by design.. I'm pretty sure there hasn't been any big insider sales.. many of the employee's have a stake.. and may be looking forward.. as far as traders (flippers) and the impatient.. they don't care.. and no one knocked on my door asking me to buy in.. so I just wait and buy/sell others.. the trend is your friend ;) IMO
$RLFTF SWX: RLF
0.51 CHF +0.078 (18.14%)
Sep 17, 5:30 PM
More Cases in Europe and a another type of outbreak (that was predicted)
WHO warns of 'very serious situation' in Europe, with 'alarming rates' of virus transmission
By Laura Smith-Spark and Vasco Cotovio, CNN
Published Sep 17, 2020
https://www.cnnphilippines.com/world/2020/9/17/coronavirus-europe-who-second-wave.html
--
Bacterial outbreak infects thousands after factory leak in China
By Jessie Yeung and Eric Cheung, CNN
Thu September 17, 2020
https://www.cnn.com/2020/09/17/asia/china-brucellosis-outbreak-intl-hnk/index.html
More Cases in Europe and a another type of outbreak (that was predicted)
WHO warns of 'very serious situation' in Europe, with 'alarming rates' of virus transmission
By Laura Smith-Spark and Vasco Cotovio, CNN
Published Sep 17, 2020
https://www.cnnphilippines.com/world/2020/9/17/coronavirus-europe-who-second-wave.html
--
Bacterial outbreak infects thousands after factory leak in China
By Jessie Yeung and Eric Cheung, CNN
Thu September 17, 2020
https://www.cnn.com/2020/09/17/asia/china-brucellosis-outbreak-intl-hnk/index.html
$NWBO Getting HOT -eom
$NWBO Getting HOT -eom
mmh I've been out of the loop.. only holding one.. ??
..they invested in mask companies.. ;)
US coronavirus: Most Americans probably can't get a Covid-19 vaccine until mid-2021, CDC director says http://a.msn.com/05/en-us/BB195RGr?ocid=st
US coronavirus: Most Americans probably can't get a Covid-19 vaccine until mid-2021, CDC director says http://a.msn.com/05/en-us/BB195RGr?ocid=st
Javitt is a keynote speaker on Monday... might mention RLF-100
https://www.sachsforum.com/20bef-investors.html
Is a Vaccine given in "doses" or a shot ?
$NWBO Stock Has Enormous Potential - https://insiderfinancial.com/nwbo-stock-has-enormous-potential/180421/
Here ya go.. send this to Dr Javitt to deal with.. another posted this on a RLFTF board to stir up drama..
COVID-19 Storms: Bradykinin In, Cytokine Out? https://www.medpagetoday.com/infectiousdisease/covid19/88560